Layton Georgia R, Sinha Shubhra, Caputo Massimo, Angelini Gianni D, Fudulu Daniel P, Zakkar Mustafa
Department of Cardiovascular Sciences, University of Leicester, Leicester LE1 7RH, UK.
Department of Cardiac Surgery, University Hospitals of Leicester NHS Trust, Leicester LE1 5WW, UK.
J Clin Med. 2024 Aug 12;13(16):4717. doi: 10.3390/jcm13164717.
: Grafting of LIMA to LAD has long been considered the gold-standard conduit choice for patients undergoing CABG. Despite this, the LSV remains the most used conduit by volume and some patients may not receive even a single arterial conduit. However, the outcomes in this group are not frequently explored. This study, therefore, compares in-hospital outcomes of patients who underwent CABG without any arterial conduits to those who received at least one arterial conduit. : Retrospective propensity-matched database analysis of consecutive patients undergoing CABG in the UK between 1996 and 2019 using data from the National Adult Cardiac Surgery Audit. : 335,144 patients underwent CABG, with 6% receiving venous conduits only; matched outcomes are reported for 39,812 patients. In both unmatched and matched groups, we found a significant increase in mortality with the use of veins only (matched mortality 5.3% vs. 3.8%, < 0.001) with estimated treatment effect for mortality OR 1.43, < 0.001 (95% CI: 1.31-1.57). We also identified greater rates of post-operative dialysis, IABP insertion, and length of hospital stay in this group. : We identified a significant increase in in-hospital mortality with the use of veins only compared to using at least one arterial graft to the LAD. While a single arterial graft should be prioritised wherever possible, venous revascularisation retains a critical role for specific patients. We must, therefore, continue to conduct research addressing the mechanisms underlying and propagating vein graft disease in order better to optimise outcomes for this niche patient group after CABG.
长期以来,左乳内动脉(LIMA)至左前降支(LAD)的移植一直被认为是接受冠状动脉旁路移植术(CABG)患者的金标准血管选择。尽管如此,大隐静脉(LSV)仍是使用量最多的血管,有些患者甚至一根动脉血管都未使用。然而,这组患者的治疗结果却鲜有研究。因此,本研究比较了未使用任何动脉血管的CABG患者与至少使用一根动脉血管的患者的院内治疗结果。
对1996年至2019年期间在英国连续接受CABG的患者进行回顾性倾向匹配数据库分析,数据来自国家成人心脏手术审计。
335144例患者接受了CABG,其中6%仅使用静脉血管;报告了39812例患者的匹配结果。在未匹配组和匹配组中,我们均发现仅使用静脉血管时死亡率显著增加(匹配后的死亡率为5.3%对3.8%,<0.001),死亡率的估计治疗效应比值比(OR)为1.43,<0.001(95%置信区间:1.31 - 1.57)。我们还发现该组患者术后透析、主动脉内球囊反搏(IABP)置入率及住院时间更长。
我们发现,与至少使用一根LAD动脉移植血管相比,仅使用静脉血管时院内死亡率显著增加。虽然应尽可能优先使用单一动脉移植血管,但静脉血管重建对于特定患者仍起着关键作用。因此,我们必须继续开展研究,探讨静脉移植血管疾病的潜在机制及发展过程,以便更好地优化这一特定患者群体CABG后的治疗效果。